Great advances have been made in the knowledge of development and
regulatory approval of medicinal product containing genetically Modified
cells. Although a guideline has been available in the EU since 2012, the
current updated version provides a useful guide to developers and
professionals involved in the regulatory process of these medicines.
This article presents the main issues communicated in that guidance, the
regulators' insights and a commentary from the academic developers'
point of view.